$57.13
-0.05-0.09%
Last update: Nov 10, 4:00 PM
BioMarin Pharmaceutical Inc
BMRNNASDAQ
BioMarin Pharmaceutical rose 8.6% from $52.67 to $57.18, behind the S&P 500's +10.0%. Its worst day was Jan 13 (−4.3%), and its low came May 18 at $49.67.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in
+17.7%, the year's best day, on 19M shares, the year's heaviest volume · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $0.46 beat the $0.36 estimate on $875.0M revenue (est. $832.9M); FY revenue guidance of $3.3B–$3.4B against the $3.4B consensus.
−0.5% · S&P 500 +0.7%
EPS of $0.76 missed the $0.89 estimate on $766.2M revenue (est. $754.6M); FY revenue guidance of $3.8B–$3.9B against the $3.7B consensus.
−4.0% · S&P 500 +0.8%
BioMarin Pharmaceutical closed at its lowest level of the year, 5.7% below where the year started.
−4.1% · S&P 500 −0.1%
BioMarin Pharmaceutical shares rose 8.6%, while the S&P 500 rose 0.2%.
+8.6% · S&P 500 +0.2%
EPS of $1.20 beat the $0.92 estimate on $990.0M revenue (est. $931.3M); FY revenue guidance of $3.9B–$3.9B against the $3.9B consensus.
+3.8% · S&P 500 +0.6%
EPS of $0.23 beat the $-0.15 estimate on $1.0B revenue (est. $1.0B); FY revenue guidance of $3.8B–$3.9B against the $3.9B consensus.
−3.1% · S&P 500 +0.3%
Where it ended: a close of $57.18 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 22, 2027 (EPS est. $1.31, revenue est. $1.1B).
Nothing in the past 12 months.
All BMRN dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BMRN and SPY from Benzinga historical bars. Not investment advice.
